Publications by authors named "A O Muck"
This review considers high-risk electrocardiographic patterns in the acute coronary syndrome (ACS) patient; we review 7 electrocardiogram presentations lacking diagnostic criteria for ST-segment elevation myocardial infarction (STEMI) yet likely representing either STEMI equivalent syndromes or ACS presentations with significant short-and long-term risk. The STEMI equivalent presentations include acute posterior wall myocardial infarction, the hyperacute T-wave of early STEMI, de Winter syndrome, first diagonal of the left anterior descending artery occlusion, and left bundle branch block modified Sgarbossa positive findings. High-risk presentation, not felt to be STEMI equivalent entities yet still possessing significant risk of short-and long-term adverse outcome, include lead aVR ST-segment elevation and Wellens syndrome.
View Article and Find Full Text PDFArticle Synopsis
- B-cell-depletion with CD20 antibodies, specifically ocrelizumab (OCR) and ofatumumab (OFA), is an effective treatment for relapsing multiple sclerosis (RMS), but their comparative effectiveness in real-world settings was previously unknown.
- A cohort study involving 1,138 RMS patients was conducted in Germany, using propensity-score matching to compare the outcomes of OCR and OFA treatment, focusing on clinical relapses, MRI lesion changes, and disability progression.
- Results showed that OFA was non-inferior to OCR in overall effectiveness, but differences were noted in patients switching from other therapies, highlighting the need for more research on these specific cases.
The evaluation of adult patients suspected of ST-segment elevation myocardial infarction (STEMI) includes a focused history and examination, 12-lead electrocardiogram (ECG), and cardiac serum marker analysis. The ECG plays a pivotal role in the early diagnosis and management of STEMI. A number of ECG entities in this patient population will present with ST-segment elevation and other electrocardiographic abnormalities which can mimic STEMI.
View Article and Find Full Text PDFArticle Synopsis
- Myasthenic crises (MC) are serious flare-ups of myasthenia gravis (MG) marked by severe muscle weakness and can lead to respiratory failure; they are typically treated with IVIG and plasma exchange.
- New therapies, such as eculizumab, ravulizumab, and efgartigimod, have been approved as add-ons for generalized AchR+ MG, but their effectiveness specifically for myasthenic crises is still untested.
- A case study of a 57-year-old man with a severe MG episode shows that after traditional treatments failed, efgartigimod significantly improved his condition within 48 hours, indicating its potential as a valuable option for treating refractory myasthen